Do analysts rate NEPH or RVP?

Nephros presently has a consensus price target of $4.00, suggesting a potential downside of 7.19%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts plainly believe Nephros is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate NEPH or LUCY?

Nephros currently has a consensus target price of $4.00, indicating a potential downside of 7.19%. Given Nephros' stronger consensus rating and higher possible upside, research analysts plainly believe Nephros is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, BMRA or NEPH?

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomerica $4.45M 1.74 -$3.78M -$1.27 N/A Nephros $18.79M 2.49 $1.19M $0.16 26.94

Is BMRA or NEPH more profitable?

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -84.79%. Nephros' return on equity of 10.60% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Biomerica -84.79% -97.19% -61.57% Nephros 8.38% 10.60% 8.05%

Which has stronger valuation & earnings, NXGL or NEPH?

Nephros has higher revenue and earnings than NexGel. NexGel is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexGel $11.42M 0.23 -$3M -$0.71 N/A Nephros $18.79M 2.49 $1.19M $0.16 26.94

Is NXGL or NEPH more profitable?

Nephros has a net margin of 8.38% compared to NexGel's net margin of -51.26%. Nephros' return on equity of 10.60% beat NexGel's return on equity. Company Net Margins Return on Equity Return on Assets NexGel -51.26% -121.18% -41.15% Nephros 8.38% 10.60% 8.05%

Nephros (NEPH) Competitors

$4.31 +0.08 (+1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.31 +0.00 (+0.09%)

As of 09/18/2026 07:55 PM Eastern

Compare

NEPH vs. RMTI, RVP, LUCY, BMRA, and NXGL

Should you buy Nephros stock or one of its competitors? Nephros's main competitors and comparable companies include Rockwell Medical (RMTI), Retractable Technologies (RVP), Innovative Eyewear (LUCY), Biomerica (BMRA), and NexGel (NXGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Nephros compare to Rockwell Medical?

Rockwell Medical (NASDAQ:RMTI) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Nephros has lower revenue, but higher earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26M	0.47	-$5.31M	-$1.34	N/A
Nephros	$18.79M	2.49	$1.19M	$0.16	26.94

In the previous week, Rockwell Medical had 7 more articles in the media than Nephros. MarketBeat recorded 7 mentions for Rockwell Medical and 0 mentions for Nephros. Nephros' average media sentiment score of 0.00 beat Rockwell Medical's score of -0.64 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Rockwell Medical	Negative
Nephros	Neutral

Rockwell Medical has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Nephros has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 4.6% of Rockwell Medical shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nephros has a net margin of 8.38% compared to Rockwell Medical's net margin of -7.33%. Nephros' return on equity of 10.60% beat Rockwell Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.33%	-14.03%	-8.90%
Nephros	8.38%	10.60%	8.05%

Rockwell Medical presently has a consensus price target of $20.00, indicating a potential upside of 148.14%. Nephros has a consensus price target of $4.00, indicating a potential downside of 7.19%. Given Rockwell Medical's higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Nephros beats Rockwell Medical on 11 of the 15 factors compared between the two stocks.

How does Nephros compare to Retractable Technologies?

Nephros (NASDAQ:NEPH) and Retractable Technologies (NYSE:RVP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Nephros has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Nephros has higher earnings, but lower revenue than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.49	$1.19M	$0.16	26.94
Retractable Technologies	$33.90M	0.64	-$7.01M	-$0.12	N/A

In the previous week, Nephros' average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score.

Company	Overall Sentiment
Nephros	Neutral
Retractable Technologies	Neutral

41.1% of Nephros shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 59.5% of Retractable Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nephros has a net margin of 8.38% compared to Retractable Technologies' net margin of -41.11%. Nephros' return on equity of 10.60% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	8.38%	10.60%	8.05%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Nephros presently has a consensus price target of $4.00, suggesting a potential downside of 7.19%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts plainly believe Nephros is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nephros beats Retractable Technologies on 12 of the 14 factors compared between the two stocks.

How does Nephros compare to Innovative Eyewear?

Nephros (NASDAQ:NEPH) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Nephros has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

Nephros has a net margin of 8.38% compared to Innovative Eyewear's net margin of -225.26%. Nephros' return on equity of 10.60% beat Innovative Eyewear's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	8.38%	10.60%	8.05%
Innovative Eyewear	-225.26%	-88.90%	-80.34%

Nephros has higher revenue and earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.49	$1.19M	$0.16	26.94
Innovative Eyewear	$2.66M	3.07	-$7.59M	-$1.29	N/A

Nephros currently has a consensus target price of $4.00, indicating a potential downside of 7.19%. Given Nephros' stronger consensus rating and higher possible upside, research analysts plainly believe Nephros is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

41.1% of Nephros shares are held by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 1.7% of Innovative Eyewear shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Innovative Eyewear had 1 more articles in the media than Nephros. MarketBeat recorded 1 mentions for Innovative Eyewear and 0 mentions for Nephros. Nephros' average media sentiment score of 0.00 equaled Innovative Eyewear'saverage media sentiment score.

Company	Overall Sentiment
Nephros	Neutral
Innovative Eyewear	Neutral

Summary

Nephros beats Innovative Eyewear on 12 of the 15 factors compared between the two stocks.

How does Nephros compare to Biomerica?

Biomerica (NASDAQ:BMRA) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.45M	1.74	-$3.78M	-$1.27	N/A
Nephros	$18.79M	2.49	$1.19M	$0.16	26.94

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 258.57%. Nephros has a consensus target price of $4.00, indicating a potential downside of 7.19%. Given Biomerica's higher possible upside, equities analysts plainly believe Biomerica is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -84.79%. Nephros' return on equity of 10.60% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-84.79%	-97.19%	-61.57%
Nephros	8.38%	10.60%	8.05%

In the previous week, Biomerica's average media sentiment score of 0.00 equaled Nephros'average media sentiment score.

Company	Overall Sentiment
Biomerica	Neutral
Nephros	Neutral

Biomerica has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Nephros has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Summary

Nephros beats Biomerica on 12 of the 14 factors compared between the two stocks.

How does Nephros compare to NexGel?

NexGel (NASDAQ:NXGL) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Nephros has a net margin of 8.38% compared to NexGel's net margin of -51.26%. Nephros' return on equity of 10.60% beat NexGel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NexGel	-51.26%	-121.18%	-41.15%
Nephros	8.38%	10.60%	8.05%

Nephros has higher revenue and earnings than NexGel. NexGel is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$11.42M	0.23	-$3M	-$0.71	N/A
Nephros	$18.79M	2.49	$1.19M	$0.16	26.94

NexGel currently has a consensus price target of $2.00, indicating a potential upside of 652.45%. Nephros has a consensus price target of $4.00, indicating a potential downside of 7.19%. Given NexGel's higher probable upside, equities research analysts clearly believe NexGel is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, NexGel had 2 more articles in the media than Nephros. MarketBeat recorded 2 mentions for NexGel and 0 mentions for Nephros. NexGel's average media sentiment score of 0.46 beat Nephros' score of 0.00 indicating that NexGel is being referred to more favorably in the media.

Company	Overall Sentiment
NexGel	Neutral
Nephros	Neutral

NexGel has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Nephros has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

2.2% of NexGel shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 19.8% of NexGel shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nephros beats NexGel on 12 of the 16 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.94M	$5.52B	$7.26B	$13.14B
Dividend Yield	N/A	1.79%	2.57%	12.30%
P/E Ratio	26.94	25.34	275.79	25.40
Price / Sales	2.49	72.24	695.58	114.47
Price / Cash	33.72	32.72	77.42	51.66
Price / Book	4.49	5.69	10.46	6.33
Net Income	$1.19M	$151.55M	$3.49B	$358.33M
7 Day Performance	-3.58%	0.66%	0.59%	1.12%
1 Month Performance	-9.45%	-3.83%	-2.01%	-2.67%
1 Year Performance	3.11%	6.86%	18.09%	6.01%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.6934 of 5 stars	$4.31 +1.9%	$4.00 -7.2%	+6.2%	$45.94M	$18.79M	26.94	36
RMTI Rockwell Medical	2.3002 of 5 stars	$8.00 +1.9%	$20.00 +150.0%	-39.4%	$31.68M	$69.26M	N/A	300	News Coverage Analyst Revision
RVP Retractable Technologies	N/A	$0.72 +5.1%	N/A	-12.7%	$21.38M	$33.90M	N/A	240
LUCY Innovative Eyewear	0.352 of 5 stars	$0.87 +5.3%	N/A	-50.5%	$7.50M	$2.66M	N/A	9
BMRA Biomerica	2.0663 of 5 stars	$2.39 +3.7%	$9.00 +277.4%	-14.3%	$7.37M	$4.45M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. RMTI, RVP, LUCY, BMRA, and NXGL

How does Nephros compare to Rockwell Medical?

Summary

How does Nephros compare to Retractable Technologies?

Summary

How does Nephros compare to Innovative Eyewear?

Summary

How does Nephros compare to Biomerica?

Summary

How does Nephros compare to NexGel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. RMTI, RVP, LUCY, BMRA, and NXGL

How does Nephros compare to Rockwell Medical?

Which has stronger earnings and valuation, RMTI or NEPH?

Does the media refer more to RMTI or NEPH?

Which has more volatility and risk, RMTI or NEPH?

Do insiders and institutionals have more ownership in RMTI or NEPH?

Is RMTI or NEPH more profitable?

Do analysts rate RMTI or NEPH?

Summary

How does Nephros compare to Retractable Technologies?

Which has more risk and volatility, NEPH or RVP?

Which has higher valuation & earnings, NEPH or RVP?

Does the media refer more to NEPH or RVP?

Do institutionals and insiders have more ownership in NEPH or RVP?

Is NEPH or RVP more profitable?

Do analysts rate NEPH or RVP?

Summary

How does Nephros compare to Innovative Eyewear?

Which has more risk & volatility, NEPH or LUCY?

Is NEPH or LUCY more profitable?

Which has stronger earnings & valuation, NEPH or LUCY?

Do analysts rate NEPH or LUCY?

Do institutionals & insiders hold more shares of NEPH or LUCY?

Does the media refer more to NEPH or LUCY?

Summary

How does Nephros compare to Biomerica?

Do insiders and institutionals believe in BMRA or NEPH?

Which has preferable valuation & earnings, BMRA or NEPH?

Do analysts prefer BMRA or NEPH?

Is BMRA or NEPH more profitable?

Does the media prefer BMRA or NEPH?

Which has more risk & volatility, BMRA or NEPH?

Summary

How does Nephros compare to NexGel?

Is NXGL or NEPH more profitable?

Which has stronger valuation & earnings, NXGL or NEPH?

Do analysts recommend NXGL or NEPH?

Does the media prefer NXGL or NEPH?

Which has more volatility & risk, NXGL or NEPH?

Do institutionals and insiders believe in NXGL or NEPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools